Show simple item record

dc.contributor.authorLópez-Muñoz, F.
dc.contributor.authorÁlamo González, C
dc.date.accessioned2018-06-22T11:35:31Z
dc.date.available2018-06-22T11:35:31Z
dc.date.issued2013
dc.identifier.issn2161-1459
dc.identifier.urihttp://hdl.handle.net/20.500.12020/748
dc.description.abstractSome antipsychotic drugs are metabolized in the liver, leading to active metabolites. These metabolites can maintain the effect of the original substrate or display different pharmacokinetic or pharmacodynamic properties, and that can be translated by a different profile of responses and interactions to clinical level. Among these is risperidone, whose active metabolite, 9-OH-risperidone, is known as paliperidone and has been marketed as such. In this review, we analyze the differential pharmacological aspects between risperidone and paliperidone, both from the pharmacokinetic (bioavailability, effect of CYP450 and P-glycoprotein, etc.) and pharmacodynamic perspectives (affinity for dopaminergic and/or serotonergic receptors, speed of dissociation from dopamine receptors, serotonin 5-HT2Areceptor occupancy>D2, etc.) as well as differential electrophysiological profile and neuroprotective role. The pharmacological differences between the two drugs could explain the differential clinical response exhibited by schizophrenic patients treated with both agents, as well as some differences in tolerability profile and drug interactions.es
dc.language.isoenes
dc.publisherJun-Ping Liues
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleThe Pharmacological Role and Clinical Applications of Antipsychotics’ Active Metabolites: Paliperidone versus Risperidonees
dc.typearticlees
dc.identifier.doihttp://dx.doi.org/10.4172/2161-1459.1000117
dc.issue.number1es
dc.journal.titleClinical and Experimental Pharmacologyes
dc.page.initial1es
dc.page.final12es
dc.rights.accessRightsopenAccesses
dc.subject.areaPsicologíaes
dc.subject.keywordActive metabolitees
dc.subject.keywordAntipsychotic drugses
dc.subject.keywordPaliperidonees
dc.subject.keywordRisperidonees
dc.subject.keywordSchizophreniaes
dc.subject.unesco3201.05 Psicología Clínicaes
dc.volume.number3es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional